Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.

Prati V, Ruatta F, Aversa C, Gernone A, Galizia D, Bonzano A, Torino S, Nuzzolese I, Marandino L, Aglietta M, Ortega C.

Future Oncol. 2018 Feb;14(5):443-448. doi: 10.2217/fon-2017-0385. Epub 2018 Jan 10.

PMID:
29318908
2.

Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.

Di Lorenzo G, Bracarda S, Gasparro D, Gernone A, Messina C, Zagonel V, Puglia L, Bosso D, Dondi D, Sonpavde G, Lucarelli G, De Placido S, Buonerba C.

Medicine (Baltimore). 2016 Jan;95(2):e2299. doi: 10.1097/MD.0000000000002299.

3.

Optimal sequence of bone target drugs in metastatic prostatic cancer.

Gernone A, Bordonaro S, Tralongo P.

Expert Rev Anticancer Ther. 2015;15(8):923-9. doi: 10.1586/14737140.2015.1054813. Epub 2015 Jun 12. Review.

PMID:
26070344
4.

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.

Caffo O, Lo Re G, Sava T, Buti S, Sacco C, Basso U, Zustovich F, Lodde M, Perin A, Facchini G, Veccia A, Maines F, Barile C, Fratino L, Gernone A, De Vivo R, Pappagallo GL, Galligioni E.

Future Oncol. 2015;11(6):965-73. doi: 10.2217/fon.14.284. Erratum in: Future Oncol. 2015;11(12):1845.

PMID:
25760977
5.

Experience with pazopanib in the treatment of metastatic renal cell carcinoma: a monocentric experience.

Gernone A.

Tumori. 2014 Jul-Aug;100(4):165e-8e. doi: 10.1700/1636.17942.

PMID:
25296611
6.

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A.

Future Oncol. 2014 Aug;10(10):1741-50. doi: 10.2217/fon.14.48. Epub 2014 Mar 18.

7.

Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.

Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Cartenì G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G.

Future Oncol. 2014 May;10(6):975-83. doi: 10.2217/fon.13.256. Epub 2013 Dec 3.

8.

Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era.

Caffo O, Gernone A, Ortega C, Sava T, Cartenì G, Facchini G, Re GL, Amadio P, Bortolus R, Pagliarulo V, Prati V, Veccia A, Galligioni E.

J Neurooncol. 2012 Mar;107(1):191-6. doi: 10.1007/s11060-011-0734-y. Epub 2011 Oct 12.

PMID:
21989810
9.

Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells.

Cafforio P, Dammacco F, Gernone A, Silvestris F.

Carcinogenesis. 2005 May;26(5):883-91. Epub 2005 Feb 10.

PMID:
15705602
10.

Endothelial cells in the bone marrow of patients with multiple myeloma.

Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, Scavelli C, Nico B, Gernone A, Battelli F, Tabilio A, Guidolin D, Petrucci MT, Ribatti D, Dammacco F.

Blood. 2003 Nov 1;102(9):3340-8. Epub 2003 Jul 10.

11.

Multiple myeloma and mycosis fungoides in the same patient: clinical, immunologic, and molecular studies.

Gernone A, Frassanito MA, Pellegrino A, Vacca A, Dammacco F.

Ann Hematol. 2002 Jun;81(6):326-31. Epub 2002 May 3.

PMID:
12107563
12.

p16 gene analysis in multiple myeloma (MM).

Gernone A, Iolascon A, Pietrafesa A, Dammacco F.

Leukemia. 1996 Aug;10(8):1401. No abstract available.

PMID:
8709653
13.
14.

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmont F, Petrucci MT, Tribalto M, Vegna ML, et al.

N Engl J Med. 1990 May 17;322(20):1430-4.

15.

Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma.

Avvisati G, Petrucci MT, Pulsoni A, Tribalto M, Lauta VM, Gernone A, Boccadoro M, Marmont F, Pileri A, Dammacco F, et al.

Eur J Haematol Suppl. 1990;52:9-11. No abstract available.

PMID:
2279547
16.

Structure of the two promoters of the human lck gene: differential accumulation of two classes of lck transcripts in T cells.

Takadera T, Leung S, Gernone A, Koga Y, Takihara Y, Miyamoto NG, Mak TW.

Mol Cell Biol. 1989 May;9(5):2173-80.

17.

Immunologic effects of long-term thymopentin treatment in patients with HIV-induced lymphadenopathy syndrome.

Silvestris F, Gernone A, Frassanito MA, Dammacco F.

J Lab Clin Med. 1989 Feb;113(2):139-44.

PMID:
2644387
18.

HBeAg/anti-HBe circulating immune complexes in patients chronically infected with hepatitis B virus.

Sansonno D, Vacca A, Gernone A, Dammacco F.

Ric Clin Lab. 1989 Jan-Mar;19(1):81-91.

PMID:
2762731

Supplemental Content

Loading ...
Support Center